Virobay Facts

2014 – Virobay appoints Thomas J. Dietz, Ph.D. to the Virobay Board of Directors more

2013 – Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain more

2013 – Virobay and LEO Pharma initiate a Phase 1 Trial of VBY-891, a compound intended for oral treatment of psoriasis more

2012 – Virobay's Cathepsin S selected as one of the Top 10 Anti-Inflammatory/Autoimmune Projects to Watch more

2012 – LEO Pharma A/S has entered into a multi-million dollar collaboration with Virobay Inc. to develop an oral treatment for psoriasis more

2010 – Virobay closes Series B financing

2008 – Virobay assets solve the chemical challenge of cathepsin inhibitor design; multiple development candidates are poised for Phase I

2007 – In-licensed cathepsin protease inhibitor assets

2007 – Filed IND and initiated Phase I trial with lead protease inhibitor as an oral treatment for Hepatitis C

2006 – Founded as a protease inhibitor drug discovery and development company



Virobay is investigating promising new approaches for the treatment of neuroapathic pain, autoimmune diseases, liver fibrosis, and cancer.

Virobay Pipeline Table
Phase 0
(Clinical Candidate)
Phase 1
Phase 2
Psoriasis - LEO Pharma     X  
Pain     X  
Autoimmunity     X  
Fibrosis/NASH     X  
Fibrosis/PBC   X    
Autoimmunity   X    
Multiple Candidates
Cancer, Alzheimer's X